Table 5.

Pooled annualized consumption of rFVIIa and aPCC in PwHAs with FVIII inhibitors across 24-week treatment intervals in the HAVEN 1, HAVEN 2, and HAVEN 4 studies

Treatment for bleed	Weeks 1-24	Weeks 25-48	Weeks 49-72	Weeks 73-96	Weeks 97-120	Weeks 121-44
Evaluable participants, n	203	192	167	125	79	57
rFVIIa AIR	5.1 (1.7-11.9)	1.2 (0.1-5.9)	2.0 (0.3-7.3)	2.3 (0.4-7.8)	2.2 (0.3-7.6)	1.4 (0.1-6.3)
rFVIIa consumption, μg/kg	657.9 (608.5-710.1)	114.3 (94.3-137.3)	202.2 (175.3-232.1)	147.3 (124.5-173.1)	171.4 (146.7-199.1)	93.5 (75.5-114.5)
aPCC AIR	1.2 (0.1-6.0)	0.5 (0-4.7)	0.1 (0-3.9)	0 (0-3.8)	0 (0-3.8)	0*
aPCC consumption, U/kg	87.8 (70.4-108.2)	11.6 (5.9-20.5)	2.9 (0.6-8.7)	0.5 (0-4.7)	0.3 (0-4.3)	0*

Unless otherwise noted, data are mean (95% CI).

^*95% CIs are not reported when all participants had a value of 0.